Fondaction CSN commits capital to AmorChem Fund II
AmorChem Group said Fondaction CSN, a Québec private equity and venture capital firm, has committed an undisclosed amount to the firm's second seed-stage biotechnology fund. AmorChem II Fund LP last year raised an initial $44.2 million from several investors, including the Québec government, Fonds de solidarité FTQ and Merck. Montréal-based AmorChem commercializes life sciences projects originating from Québec universities and research centres. In March, it backed the $2.6 million financing of biotechnology startup SemaThera Inc.
13 April 2018•3 mins read
